NSABP B-59
NSABP B-59
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Aztezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo
Protocol Chair: Charles E. Geyer, MD
Protocol Officer: Priya Rastogi, MD
Patient Population:
Patients with high risk triple-negative breast cancer
Target Accrual: 1520 patients
Status: Active, Not Recruiting
ClinicialTrials.gov Identifier: NCT03281954
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Aztezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo
Protocol Chair: Charles E. Geyer, MD
Protocol Officer: Priya Rastogi, MD
Patient Population:
Patients with high risk triple-negative breast cancer
Target Accrual: 1520 patients
Status: Active, Not Recruiting
ClinicialTrials.gov Identifier: NCT03281954